Skip to content

Genetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin

Search for Genetic Markers and Biomarkers to Follow Patients With Intellectual Disabilities of Genetic Origin and to Understand Its Origin and Associated Comorbidities

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05767203
Acronym
BioJeL
Enrollment
2000
Registered
2023-03-14
Start date
2022-09-01
Completion date
2032-12-31
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down Syndrome, Intellectual Disability

Brief summary

Analyze genetic and biological markers in patients with Intellectual Deficiencies (ID) of genetic origin in order to better understand the mechanisms of modified genes, cellular mechanisms, pathways involved in different disorders , complications and pathologies associated with ID of genetic origin.

Detailed description

Blood and skin samples will be taken from patients coming at the outpatients clinic of the Institut Jérôme Lejeune and who consent to participate to the study. Search and identification of markers will be then done from the collected samples.

Interventions

Blood and/or skin samples

Sponsors

Institut Jerome Lejeune
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patient diagnosed with an intellectual disability of genetic origin * Patient of all ages coming for consultation at the Institut Jérôme Lejeune * Patient whose parents or legal representative have received and understood the information document and signed the informed consent for a sample for the research project. * Patient affiliated to a social security scheme

Exclusion criteria

* Parents unable to find out about the constraints related to the study * Refusal of informed patient participation * Pregnant, parturient and nursing mothers * Persons deprived of their liberty by judicial or administrative decision

Design outcomes

Primary

MeasureTime frameDescription
Identification of biomarkers in blood10 yearsAnalysis of biomarkers from blood samples taken during the visit
Identification of biomarkers from skin samples10 yearsAnalysis of biomarkers from skin samples taken during the visit

Countries

France

Contacts

Primary ContactSophie Durand
sophie.durand@institutlejeune.org+33156586300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026